Mölnlycke have moved inBy Jamie Smith - 13 Dec 2017
Building cell biology and analytical chemistry capabilities and exploring collaboration opportunities across life science, Mölnlycke have moved into AstraZeneca’s BioVentureHub.
Collaboration agreements are already being drafted, learnings are being generated and barriers are being broken. Here are four perspectives on the move…
Ewa Kölby Falck leads the Mölnlycke team located in the BioVentureHub.
Magnus Björsne, CEO for AstraZeneca’s BioVentureHub CEO, is delighted to welcome another global life science company to the AstraZeneca Gothenburg site.
Marina Craig is a Mölnycke scientist located in the BioVentureHub. She’s excited about the opportunity to dig deeper into the science together with AstraZeneca experts.
Iris Öhrn, is Business Region Göteborg’s life science investment advisor. She sees that the collaboration between Mölnlycke and AstraZeneca can bring additional benefits to the life science industry in West Sweden.
- Mölnlycke to establish R&D innovation unit in AstraZeneca BioVentureHub
- Mölnlycke (website)
- AstraZeneca BioVentureHub (website)